Sigachi Launches New Hyderabad R&D Centre to Strengthen API Innovation
On June 18, 2025, Sigachi Industries opened a new research and development (R&D) centre in Hyderabad. This new facility is designed to speed up the creation and testing of Active Pharmaceutical Ingredients (APIs), which are the key ingredients in many medicines. The goal is to improve how quickly and safely new drugs are developed, tested, and brought to global markets.
This step also fits well with Hyderabad's rise as a global pharma hub. From well-known hospitals to cutting-edge biotech firms, the city supports health-focused companies like Sigachi. It's also one of the reasons why premium housing projects such as Godrej Regal Pavilion are seeing increased demand from professionals in this area.
The new Hyderabad centre will bring together Sigachi's API research and regulatory work under one roof. Here's what the company aims to achieve:
With the research and testing happening in one place, the company hopes to cut down the time needed to bring new drug ingredients to market.
The new facility is built to meet international quality and safety standards. This means Sigachi can file approvals faster in markets like the US and Europe.
Sigachi has invested about ₹8.3 crore (around $1 million) into this project. The money is focused on developing advanced APIs and complex drug components that are in demand across the world.
The R&D team will focus on high-need therapeutic areas such as heart disease and cancer, where new treatments are urgently needed.
The facility is equipped with modern labs, high-tech tools, and a team of 15–20 experienced scientists. Their main tasks will include:
- Conducting safety and stability tests
- Preparing documents for international regulatory bodies
- Using data to predict how new drugs will behave during manufacturing and storage
The centre is also part of a larger push by Sigachi to move into newer areas like:
- Croscarmellose Sodium (CCS), expected to be launched in 18 months
- Co-processed MCC blends
- 3D printed medicines and nutraceuticals
Amit Raj Sinha, CEO and Managing Director of Sigachi, said the R&D centre is a key part of the company's long-term growth strategy.
"This centre gives us the tools and the people we need to deliver better, faster, and more efficient solutions to the global market," he said.
His statement reflects the company's plan to move beyond just being a top excipient manufacturer and become a serious player in the API space.
Just days after the centre opened, Sigachi faced a major setback. On June 30, 2025, a fire broke out at its Pashamylaram facility, where Microcrystalline Cellulose (MCC) is produced. Early reports suggested a reactor blast, but later updates revealed it was likely a dust explosion in the dryer section.
Sadly, the incident led to multiple worker deaths and injuries. The company announced ₹1 crore compensation for each affected family and promised full support to the injured. Production at the unit has been paused for 90 days. To make up for the lost capacity, Sigachi is ramping up production at its Gujarat plants.
Hyderabad continues to attract top pharma and biotech companies. The new Sigachi R&D facility adds to this momentum. It also creates opportunities for related industries, including real estate. With many professionals looking for quality housing near their workplaces, projects like Godrej Regal Pavilion in Kokapet are becoming increasingly popular.
Sigachi's new research centre in Hyderabad is more than just a building—it's a clear sign of the company's commitment to innovation, speed, and quality. While the recent fire at its other plant is a tragic reminder of the risks involved in pharmaceutical manufacturing, the company's response has been quick and responsible.
As Sigachi moves forward, it shows strength in both its science and its leadership. For the city of Hyderabad, this is another step forward in becoming a leading global hub for pharma innovation.
| Enquiry |